Aradigm Corporation  

(Public, OTCMKTS:ARDM)   Watch this stock  
Find more results for OTC:ARDM
0.214
-0.001 (-0.23%)
Apr 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.21 - 0.22
52 week 0.09 - 0.40
Open 0.22
Vol / Avg. 105,481.00/291,607.00
Mkt cap 125.97M
P/E     -
Div/yield     -
EPS -0.06
Shares 587.25M
Beta 0.41
Inst. own 33%
Mar 24, 2014
Q4 2013 Aradigm Corporation Earnings Release (Estimated)
Feb 11, 2014
Aradigm Corporation at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -14.12% -221.92%
Operating margin -4.87% -204.92%
EBITD margin - -36.76%
Return on average assets -5.02% -72.62%
Return on average equity -7.74% -133.76%
Employees 11 -
CDP Score - -

Address

3929 Point Eden Way
HAYWARD, CA 94545
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

Description

Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company's lead development candidates are formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)), which is delivered by inhalation for the management of infections associated with the severe respiratory diseases cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE).

Officers and directors

Virgil D. Thompson Independent Chairman of the Board
Age: 73
Igor Gonda Ph.D. President, Chief Executive Officer, Director
Age: 65
Nancy E. Pecota Chief Financial Officer, Vice President - Finance
Age: 53
David Bell Director
Lafmin Morgan Director
John M. Siebert Ph.D. Independent Director
Age: 73